| Literature DB >> 35352505 |
Qiongqiong Xu1,2,3,4,5, Xiaodong Zheng1,2,3,4,5, Yiwen Mao1,2,3,4,5, Weiwei Chen1,2,3,4,5, Shirui Chen1,2,3,4,5, Hui Zhang1,2,3,4,5, Qi Zhen1,2,3,4,5, Bao Li1,2,3,4,5, Liang Yong1,2,3,4,5, Huiyao Ge1,2,3,4,5, Yafen Yu1,2,3,4,5, Ruixue Zhang1,2,3,4,5, Lu Cao1,2,3,4,5, Hui Cheng1,2,3,4,5, Wenjun Wang1,2,3,4,5, Liangdan Sun1,2,3,4,5.
Abstract
BACKGROUND/AIMS: Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by excessive proliferation of keratinocytes. It has a strong genetic predisposition; gene-gene interactions are important genetic models for common diseases. In this study, we explore pair-wise interactions among SNPs contributing to psoriasis susceptibility.Entities:
Keywords: zzm321990HLAzzm321990; gene-interactions; psoriasis
Mesh:
Substances:
Year: 2022 PMID: 35352505 PMCID: PMC9034666 DOI: 10.1002/mgg3.1858
Source DB: PubMed Journal: Mol Genet Genomic Med ISSN: 2324-9269 Impact factor: 2.473
FIGURE 1The optimal p‐value for psoriasis using polygenic risk score (PRS) analysis
Interaction analysis in exome and targeted sequencing data
| SNP1 | SNP2 | OR |
| Gene 1 | Gene 2 |
|---|---|---|---|---|---|
| chr14_64897018 | chr19_10464687 | 0.5653 | 2.34E‐05 | MIR548AZ | TYK2 |
| chr16_11363025 | chr17_78171944 | 3.954 | 2.34E‐05 | CARD14 | TNP2 |
| chr14_64897018 | chr19_10472933 | 0.5768 | 2.35E‐05 | MIR548AZ | TYK2 |
| chr5_158705065 | chr10_75564624 | 0.302 | 2.85E‐05 | NDST2 | UBLCP1 |
| chr1_234565787 | chr9_32633719 | 7.783 | 8.06E‐05 | TAF1L | TARBP1 |
| chr14_64896783 | chr19_10472933 | 0.594 | 8.95E‐05 | MIR548AZ | TYK2 |
| chr14_64896783 | chr19_10464687 | 0.5831 | 9.56E‐05 | MIR548AZ | TYK2 |
| chr5_158750013 | chr12_56398287 | 0.2036 | 9.63E‐05 | IL12B | SUOX |
Interaction analysis in exome, targeted and HLA sequencing data
| Vatiant 1 | Vatiant 2 | OR |
| Gene 1 | Gene 2 |
|---|---|---|---|---|---|
| HLA‐C*06:02 | rs118179173 | 0.22 | 8.21E‐20 | HLA‐C | HLA‐B |
| HLA‐C*06:02 | HLA‐B:AA67 | 0.45 | 1.22E‐12 | HLA‐C | HLA‐B |
| chr5_96139250 | HLA‐C*06:02 | 0.74 | 3.61E‐07 | ERAP1 | HLA‐C |
| chr5_96117300 | HLA‐C*06:02 | 0.75 | 1.68E‐06 | ERAP1 | HLA‐C |
| HLA‐C*06:02 | HLA‐C*07:04 | 0.28 | 6.86E‐06 | HLA‐C | HLA‐C |
| chr5_96118852 | HLA‐C*06:02 | 0.78 | 3.43E‐05 | ERAP1 | HLA‐C |
| chr5_96125910 | HLA‐C*06:02 | 0.78 | 3.81E‐05 | ERAP1 | HLA‐C |
| snp31443520 | HLA‐DPB1*05:01 | 1.47 | 6.07E‐05 | HLA‐B | HLA‐DPB1 |
| chr5_96124447 | HLA‐C*06:02 | 0.79 | 6.44E‐05 | ERAP1 | HLA‐C |
| chr5_96121994 | HLA‐C*06:02 | 0.79 | 6.50E‐05 | ERAP1 | HLA‐C |
| chr5_96121715 | HLA‐C*06:02 | 0.79 | 6.96E‐05 | ERAP1 | HLA‐C |
| chr5_96129512 | HLA‐C*06:02 | 0.80 | 0.0002089 | ERAP1 | HLA‐C |
| chr5_96222183 | HLA‐C*06:02 | 0.80 | 0.0002627 | ERAP2 | HLA‐C |
| HLA‐C*06:02 | HLA‐DPB1*05:01 | 1.26 | 0.0002793 | HLA‐C | HLA‐DPB1 |
| chr5_96222185 | HLA‐C*06:02 | 0.81 | 0.0005506 | ERAP2 | HLA‐C |
| chr5_96232222 | HLA‐C*06:02 | 0.82 | 0.0009334 | ERAP2 | HLA‐C |
| chr5_96237114 | HLA‐C*06:02 | 0.82 | 0.0009459 | ERAP2 | HLA‐C |
| chr5_96132795 | HLA‐C*06:02 | 0.77 | 0.0009922 | ERAP1 | HLA‐C |
Interactions between HLA and ERAP1
| SNP1 | SNP2 | OR |
| Gene 1 | Gene 2 |
|---|---|---|---|---|---|
| C*06:02 | 5_96139250 | 0.74 | 3.61E‐07 |
|
|
| C*06:02 | 5_96117300 | 0.75 | 1.68E‐06 |
|
|
| C*06:02 | 5_96118852 | 0.78 | 3.43E‐05 |
|
|
| C*06:02 | 5_96125910 | 0.78 | 3.81E‐05 |
|
|
| C*06:02 | 5_96124447 | 0.79 | 6.44E‐05 |
|
|
| C*06:02 | 5_96121994 | 0.79 | 6.50E‐05 |
|
|
| C*06:02 | 5_96121715 | 0.79 | 6.96E‐05 |
|
|
| C*06:02 | 5_96129512 | 0.80 | 0.0002089 |
|
|
| C*06:02 | 5_96132795 | 0.77 | 0.0009922 |
|
|